Clinical bottom line
Chronic uterine inflammation, including conditions such as chronic endometritis and adenomyosis, is increasingly recognized as a potentially modifiable factor impacting female fertility and assisted reproductive technology (ART) outcomes. Emerging evidence suggests that targeted diagnosis and management of chronic uterine inflammation may improve implantation rates and pregnancy success, though definitive clinical protocols remain under development. Clinicians should consider chronic uterine inflammation in the differential diagnosis of infertility, especially in cases of recurrent implantation failure or unexplained infertility, while awaiting further validation of optimal diagnostic and therapeutic strategies.
What the evidence shows
Chronic uterine inflammation encompasses a spectrum of pathologies characterized by persistent inflammatory changes within the endometrium and myometrium. Chronic endometritis, often subclinical, involves infiltration of plasma cells and altered immune cell profiles, which may disrupt endometrial receptivity and embryo implantation (de Ziegler et al., 2019). Similarly, adenomyosis, characterized by ectopic endometrial tissue within the myometrium, is associated with local inflammation and fibrosis, potentially impairing uterine contractility and embryo implantation (Donnez et al., 2024).
Recent reviews highlight the inflammatory mechanisms linking these uterine conditions to infertility. Rathod et al. (2024) comprehensively describe how pro-inflammatory cytokines, altered immune cell populations, and fibrosis contribute to a hostile uterine environment that compromises fertility. Moïse et al. (2025) emphasize the importance of thorough gynecological examination and targeted biopsy to identify chronic endometritis in patients with infertility or recurrent implantation failure.
Therapeutic interventions targeting chronic uterine inflammation are evolving. Antibiotic regimens for chronic endometritis have shown promise in improving pregnancy rates in some cohorts, though standardized treatment protocols and diagnostic criteria vary (de Ziegler et al., 2019). For adenomyosis, medical therapies aimed at reducing inflammation and fibrosis, such as hormonal suppression, are under investigation, with some evidence suggesting improved in vitro fertilization (IVF) outcomes following treatment (Donnez et al., 2024).
Saleem Azam et al. (2025) discuss the broader context of reproductive endocrine disorders, including endometriosis and adenomyosis, underscoring the complex interplay between inflammation, hormonal dysregulation, and infertility. The cumulative evidence supports a putative role for chronic uterine inflammation as a contributor to subfertility and ART failure, warranting further research into precise diagnostic markers and individualized treatment approaches.
Caveats and uncertainty
Despite growing interest, the field faces several limitations. Diagnostic criteria for chronic endometritis lack standardization, with variability in histopathological thresholds and the role of immunohistochemical markers. The clinical significance of mild versus severe inflammation remains unclear. Similarly, the heterogeneity of adenomyosis phenotypes complicates assessment of its direct impact on fertility outcomes.
Most available data derive from observational studies or small cohorts, limiting causal inference. Randomized controlled trials evaluating the efficacy of anti-inflammatory or antibiotic therapies on fertility endpoints are sparse. Additionally, confounding factors such as coexisting endometriosis, uterine fibroids, or systemic inflammatory conditions may influence outcomes and are not consistently accounted for.
The optimal timing and modality of intervention, including whether treatment should precede ART cycles, remain to be defined. Furthermore, the impact of chronic uterine inflammation on natural conception versus assisted reproduction may differ, necessitating tailored clinical pathways.
How this may change practice
Clinicians managing infertility should maintain a high index of suspicion for chronic uterine inflammation in patients with unexplained infertility or repeated ART failures. Incorporating targeted endometrial sampling and histopathological evaluation into infertility workups may identify candidates for therapeutic intervention.
Pending further evidence, empiric antibiotic treatment for confirmed chronic endometritis may be considered in selected cases, with close monitoring of reproductive outcomes. For patients with adenomyosis, individualized counseling regarding potential impacts on IVF success and consideration of medical or surgical management options may optimize outcomes.
Multidisciplinary collaboration among reproductive endocrinologists, pathologists, and gynecologic surgeons will be essential to refine diagnostic algorithms and treatment protocols. Future integration of molecular and immunological biomarkers may enhance precision medicine approaches in this domain.
Overall, advances in understanding chronic uterine inflammation offer a promising avenue to improve fertility care, but clinicians should apply current evidence cautiously and in the context of comprehensive patient evaluation.